---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-025666"
form_type: "8-K"
ticker: "FLGT"
cik: "0001674930"
company_name: "Fulgent Genetics, Inc."
filed_at: "2022-11-23T23:59:59+00:00"
generated_at: "2026-06-21T13:26:34.380111+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Fulgent Genetics receives Nasdaq non-compliance letter for audit committee shortage; cure period to Oct 2023

## Summary
- Received Nasdaq letter Nov 18, 2022: audit committee has 2 independent directors instead of required 3.
- Cure period expires at earlier of next annual meeting or Oct 31, 2023; if meeting before May 1, 2023, then May 1, 2023.
- Company plans to appoint an additional independent director to regain compliance.
- No immediate impact on listing or trading of FLGT common stock on Nasdaq.

## SEC filing metadata
- accession: 0000950170-22-025666
- form_type: 8-K
- ticker: FLGT
- cik: 0001674930
- company_name: Fulgent Genetics, Inc.
- filed_at: 2022-11-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674930/000095017022025666/0000950170-22-025666-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674930/000095017022025666/flgt-20221118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-025666
- JSON: https://secwatch.observer/filing/0000950170-22-025666.json
- Plain text: https://secwatch.observer/filing/0000950170-22-025666.txt

## Key facts
- Listing & Compliance Notices
  Fulgent Genetics, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: audit committee
  - Rules: 5605
  source text: November 18, 2022, Fulgent Genetics, Inc. (the “Company”) received a letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was no longer in compliance with the audit committee requirements as set forth in Nasdaq Listing Rule 5605, which requires the Audit Committee of the Board of Directors of the Company (the “Audit Committee”) to be comprised of a minimum of three independent directors. The Audit Committee is currently comprised of two independent directors and one vacancy. The Letter provides that the Company is eligible for a cure period in which to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674930/000095017022025666/0000950170-22-025666-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.